Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
HOME > TRENDS
TRENDS
-
Pharmas’ Rep Number Corrections in Full Force amid Bleak Market Outlook, Silver Lining Seen in “Specialty” Arena
August 18, 2017
-
Top Drugs Jostling for Higher Share amid Tepid Market, Trulicity Overtakes Victoza in GLP Space: April-June
August 7, 2017
-
Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally
June 28, 2017
-
Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
April 10, 2017
-
Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
-
As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
-
Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
-
Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
February 7, 2017
-
AGs Set to Break into 10 Billion Yen Territory in Japan
November 14, 2016
-
Gilead Stays Pat on Hep C Plan, Japan Chief Says Innovation Outstrips Re-Pricing Hit
October 18, 2016
-
Japan’s Established Drug Market Shines as Renewed Opportunity for Foreign Generic Firms
September 26, 2016
-
Sumitomo Dainippon Feeling Sense of Crisis about Operating Profit to Approach Zero; Will Offer Early Retirement and Cut Executive Compensation
September 15, 2016
-
Surprise Rule Change Pops Up Yet Again, This Time with Taltz
September 5, 2016
-
Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
June 21, 2016
-
Success of Daiichi Sankyo’s New Midterm Plan to Hinge on Edoxaban; 120 Billion Yen Sales Target Set for FY2020
April 13, 2016
-
Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
February 17, 2016
-
Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
-
17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
ページ
“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…